MRI and MET-PET treatment evaluation in glioblastoma

PROSPECTIVE LONGITUDINAL STUDY USING FUNCTIONAL MRI AND MET-PET IMAGING FOR TREATMENT EVALUATION IN GLIOBLASTOMA PATIENTS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON23945

Enrollment

Registered

2017-09-28

Start date

2018-01-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Interventions

This study aims to establish the diagnostic accuracy of functional MRI techniques and MET-PET individually and combined in treatment evaluation of glioblastoma.

Eligibility

Inclusion criteria

Inclusion criteria: - Adult patients with a new primary glioblastoma - Scheduled to undergo standard treatment consisting of surgical resection followed by concomitant chemoradiation and adjuvant chemotherapy according to the Stupp protocol - Informed consent must be obtained - No exclusion criteria

Exclusion criteria

Exclusion criteria: - Patients with a recurrent or secondary glioblastoma - Patients with other intracranial tumours - Patients with infratentorial glioblastoma - Prior brain surgery or irradiation of the head - Patients not scheduled for standard therapy (e.g. who will receive a biopsy without further resection) - Minors (< 18 years of age)

Design outcomes

Primary

Measure	Time frame
The primary outcome is to establish the diagnostic accuracy of functional MRI techniques and MET-PET individually and combined in treatment evaluation of glioblastoma.	—

Contacts

Public ContactA. Hoorn, van der

Department of radiology (EB44), University Medical Center Groningen

a.van.der.hoorn@umcg.nl+31503616161

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)